Healthcare Capital Corp Class A HCCC 深 沪
等待开盘 08-25 09:30:00 美东时间
12.74
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 12.74
- 总市值 43.79万
- 52周最高 14.78
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 8.20
- 委 比 0.00%
- 总股本 3.44万
- 历史最高 14.78
- 量 比 0
- 振 幅 0.00%
- 历史最低 8.20
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Announces Second Quarter 2026 Financial Results and Business Updates
Entera Bio Ltd. reported financial results and updates for Q2 2026, highlighting FDA alignment on a 12-month Phase 3 study for EB613, an oral anabolic tablet for postmenopausal osteoporosis. The company secured $275M in private placement led by BVF Partners to fund EB613's development through NDA submission. EB613's Phase 3 initiation is planned for late 2026, with topline data expected in H2 2028. Additionally, preclinical data for EB612, an ora...
08-07 20:05
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
NextCure and Avere Therapeutics have agreed to merge in an all-stock transaction, with the combined company to operate as Avere Therapeutics, Inc. Avere’s lead program, AVR-001, is a once-weekly oral IL-23 receptor antagonist showing promise in psoriasis. A $320 million private investment will support its development through Phase 2b and Phase 3 trials. The merger is expected to close in 2026, with Avere’s team, including CEO Andrew Cheng, leadin...
07-14 10:00
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Artiva Biotherapeutics announced an underwritten offering of 23,871,526 shares of common stock at $11.52 per share and pre-funded warrants for 2,170,138 shares, raising approximately $300 million. The offering includes participation from major investors and is expected to close on May 11, 2026. Artiva, a biotech company focused on developing cell therapies for autoimmune diseases, plans to use the proceeds to advance its AlloNK program, targeting...
05-08 10:52
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio reported Q1 2026 progress, highlighting KRRO-121's potential as a first-in-class treatment for hyperammonemia in urea cycle disorders and hepatic encephalopathy, with regulatory filing expected in H2 2026. The company advanced its GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency, achieving >90% in vivo RNA editing. Korro executed an $85M private placement to extend cash runway into H2 2028 and support multiple RNA ed...
05-07 11:00
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
Century Therapeutics reported financial results for 2025 and highlighted progress in developing cell therapies for type 1 diabetes and cancer. The company expects to submit an IND for CNTY-813, a potential functional cure for type 1 diabetes, in Q4 2026, with initial clinical data anticipated in H2 2027. CNTY-308, targeting B-cell-mediated diseases, is on track to enter the clinic in 2026. Century strengthened its balance sheet with a $135 millio...
03-12 12:00
Korro Bio Secures ~$85M PIPE Financing Via Subscription Agreement
Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs
03-09 19:36
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
Relmada Therapeutics, a biotechnology company, has secured approximately $160 million through a PIPE financing, with participation from leading investors. The transaction includes 29.47 million common shares and pre-funded warrants for 4.21 million shares. Proceeds will support working capital, general corporate purposes, and advancing R&D efforts. The financing is expected to close on March 11, 2026.
03-09 11:05
快讯 | Newmark任命Justin Shepherd为美国医疗保健资本市场团队的联席负责人
Newmark Appoints Justin Shepherd as Co-Head of U.S. Healthcare Capital Markets ...
2025-03-13 01:04
